FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

Summary by AI BETAClose X

OKYO Pharma Limited announced that the FDA has authorized a single-patient compassionate use IND for urcosimod (0.05%) to treat a patient with severe neuropathic corneal pain, a condition with no currently approved FDA treatments. This authorization supports the investigational therapy's potential dual mechanism of action targeting inflammation and nerve signaling. The company also confirmed its plan to initiate a 120-patient Phase 2b/3 study for urcosimod in neuropathic corneal pain this year, following positive Phase 2 data in both neuropathic corneal pain and dry eye disease.

Disclaimer*

UK 100

Latest directors dealings